Results 51 to 60 of about 6,174 (184)
Case Reports in Oncology, 2022 Encorafenib plus binimetinib combination therapy is one of the first-line therapies for advanced melanoma, and it is known to cause a different profile of adverse events (AEs) than dabrafenib plus trametinib combination therapy.
Yumi Kambayashi +6 more
doaj +1 more source
Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference [PDF]
, 2017 There has been significant progress in the understanding of the pathology and molecular biology of rare ovarian cancers, which has helped both diagnosis and treatment.
Bookman, M +18 more
core +2 more sources
Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs
Clinical Pharmacology &Therapeutics, EarlyView.Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri +10 more
wiley +1 more source
International Journal of Cancer, EarlyView.What's New? Patient‐derived organoids (PDOs) model tumor biology and drug response while preserving key tumor features, yet the impact of non‐genetic culture variables is poorly understood. This study examined the influence of organoid size, seeding density, and morphology on growth, drug sensitivity, and Wnt signaling in a colorectal cancer organoid ...
Viktoria Zieger +6 more
wiley +1 more source
Frontiers in Pigment Cell and Melanoma Research
, 2018 We identify emerging frontiers in clinical and basic research of melanocyte biology and its associated biomedical disciplines. We describe challenges and opportunities in clinical and basic research of normal and diseased melanocytes that impact current ...
Birlea, Stanca +26 more
core +1 more source
Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents [PDF]
, 2016 For several decades, cytotoxic chemotherapeutic agents were considered the basis of anti-cancer treatment for patients with metastatic tumors. A decrease in tumor burden, assessed by volumetric computed tomography (CT) and magnetic resonance imaging (MRI)
Natalie J. Serkova, S. Gail Eckhardt
core +2 more sources
Magnetic Resonance in Medicine, EarlyView.ABSTRACT Purpose We aim to inform the design of new diffusion MRI (dMRI) approaches for microvasculature quantification that enhance the biological specificity of imaging towards cancer. Methods We adopted simulation‐informed modelling of the vascular dMRI signal. We synthesised signals from 1500 synthetic vascular networks, for a variety of protocols (
Anna Kira Voronova +11 more
wiley +1 more source
Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. [PDF]
, 2017 Metastatic melanoma is a highly aggressive disease. Recent progress in immunotherapy (IT) and targeted therapy (TT) has led to significant improvements in response and survival rates in metastatic melanoma patients.
Ahmad +50 more
core +2 more sources
Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review
British Journal of Pharmacology, EarlyView.Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos +16 more
wiley +1 more source
Clinical implications of epithelial cell plasticity in cancer progression [PDF]
, 2015 Mini-review[Abstract] In the last few years, the role of epithelial cell plasticity in cancer biology research has gained increasing attention. This concept refers to the ability of the epithelial cells to dynamically switch between different phenotypic ...
Antón-Aparicio, Luis M. +6 more
core +2 more sources